In summary, in this phase I study, RC48 showed preliminary anti-tumor activity and a manageable safety profile in patients with advanced HER2-positive gastric cancer, including those with HER2 2+/FISH−, and those pre-treated with HER2-targeted drugs. The gene discussed is ERBB2; the disease is gastric cancer.